MIGUEL ANGEL
SANZ ALONSO
CATEDRÁTICO/A DE UNIVERSIDAD
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (11)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Lactobacillus supports Clostridiales to restrict gut colonization by multidrug-resistant Enterobacteriaceae
Nature Communications, Vol. 13, Núm. 1
2021
-
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Cancer, Vol. 127, Núm. 12, pp. 2003-2014
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
2019
-
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155
2015
-
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Haematologica
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300
2011
-
Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
Haematologica, Vol. 96, Núm. 10, pp. 1448-1456